Low participant enrolment

This Phase IIa, randomized, double-blind, placebo-controlled, parallel group study will evaluate the safety, efficacy and pharmacodynamics of basmisanil in adult participants with severe motor impairment following an ischemic stroke.

Inclusion Criteria:

• Radiologic assessment confirming an acute middle cerebral artery ischemic stroke
• Index stroke occurred within the past 3-4 days
• Inpatient males and females
• Severe hemiparesis or hemiplegia defined by FMMS score less than or equal to (</=) 35
• Sufficient speech, vision and hearing to participate in study evaluations

Exclusion Criteria:

• NIHSS greater than (>) 20
• Severe aphasia that prevents a participant from following directions in rehabilitation
• Significant deficit from prior strokes or pre-existing motor deficit
• History of epilepsy, neurosurgery, severe head trauma or central nervous system infections that have residual symptomatology or have required treatment in the last 12 months
• Known or suspected clinical seizure post-index stroke
• History of pre-existing dementia or use of medications for dementia
• History of clinically significant pre-existing psychiatric conditions within 12 months prior to stroke
• Due to undergo carotid surgery within the next 4 months
• Enrollment/participation in any interventional study (clinical trial) involving an investigational drug (unapproved) or non-drug treatment within the prior 3 months or 6 times the half-life (whichever is longer)
• Clinically relevant medical conditions that would likely interfere with the study conduct and scheduled assessments
• Contraindication to magnetic resonance imaging (MRI) or conditions which render interpretation of MRI difficult